FAP-2286 and Clovis' Targeted Radionuclide Therapy Development Program
In September 2019, Clovis and 3B Pharmaceuticals GmbH (3BP) entered into a global licensing and collaboration agreement with an initial focus on developing FAP-2286, a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP).
FAP-2286, is Clovis Oncology’s peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP) and is the lead candidate in the Company’s targeted radionuclide therapy development program. FAP-2286 is a clinical candidate under investigation as a PTRT and imaging agent targeting fibroblast activation protein (FAP). FAP-2286 consists of two functional elements; a targeting peptide that binds to FAP and a site that can be used to attach radioactive isotopes for imaging and therapeutic use. FAP is highly expressed on cancer-associated fibroblasts (CAFs) in many epithelial cancers, including more than 90% of breast, lung, colorectal, and pancreatic carcinomas.[i] The Phase 1/2 LuMIERE study of FAP-2286 is expected to open for enrollment in the second quarter of 2021. Clovis holds US and global rights for FAP-2286 excluding Europe, Russia, Turkey, and Israel. FAP-2286 is an unlicensed medical product.
Clovis also has global rights to three additional discovery-stage compounds in its targeted radionuclide development program.
[i] Rettig WJ et al. Regulation and Heteromeric Structure of the Fibroblast Activation Protein in Normal and Transformed Cells of Mesenchymal and Neuroectodermal Origin. Cancer Res. 1993;53:3327–3335.
FAP-2286 Scientific Presentations
Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy to fibroblast activation protein alpha
Poster Presentation 2020 ESMO Virtual Meeting